"Designing Growth Strategies is in our DNA"

U.S. Diabetes Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Others), By Diabetes Type (Type 1 and Type 2), By Route of Administration (Oral, Subcutaneous, and Intravenous), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies), and Country Forecast, 2023-2030

Last Updated: October 21, 2024 | Format: PDF | Report ID: FBI109115

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The U.S. diabetes drugs market size was worth USD 30.47 billion in 2022 and is projected to grow at a CAGR of 7.6% during the forecast period.


The prevalence of diabetes is increasing across the U.S. owing to poor diet, lack of physical activity, sedentary lifestyle, and obesity in all age groups among the population. This scenario has led to an increased demand for advanced diabetes drugs, further propelling market growth.



  • As per statistics published by the Census Bureau in November 2022, about 37 million Americans, including adults and youth, suffer from diabetes.


The COVID-19 pandemic had a negative impact on the market progress in 2020, owing to a decline in the sales of diabetes drugs across retail channels and disruptions in the supply chain of these drugs across the globe.


U.S. Diabetes Drugs Market Trends


Rise in Presence of Biosimilars Across the Country


The demand for cost-effective diabetes drugs is increasing among the population owing to the high cost of conventional drugs used for the treatment of this ailment. Thus, several key players are now focusing on introducing safe, high-quality, and biologically similar products nationwide for treating diabetes.



  • In April 2023, Lilly launched its insulin glargine biosimilar, Rezvoglar (insulin glargine-aglr), in the U.S. market for the treatment of diabetes.


Therefore, the rising introduction of biosimilar drugs by key players and the rise in patient awareness will aid the U.S. diabetes drugs market growth.


U.S. Diabetes Drugs Market Growth Factors


Rising Use of Inorganic Strategies by Industry Players to Augment Market Development


The leading market players in the U.S. are emphasizing the development of advanced drugs that are similar to traditional diabetes drugs, such as insulin glargine, by acquiring other key players in the market.



  • In November 2022, Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced the acquisition of the global biosimilar business of its partner Viatris Inc. The collaboration resulted in the launch of an interchangeable biosimilar semglee (insulin glargine-yfgn) injection in November 2021. The injection will help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.


Such initiatives will further expand the existing diabetes drugs product portfolio of key players, thereby propelling market growth.


RESTRAINING FACTORS


High Cost of Diabetes Drugs to Restrain Market Growth


The financial burden of diabetes treatment on the U.S. population is high. Moreover, prices of advanced diabetes drugs, such as insulin, are rising due to the high costs sustained by key players from introducing incremental improvements to the processing of these drugs.



  • According to an article published by PETERSON-KFF Health System Tracker in August 2023, the cost of Ozempic drugs in the U.S. is around USD 936 compared to the U.K. and France, where the price of these medicines is USD 100 and USD 83, respectively.


Thus, the high price of diabetes treatment in the U.S. compared to other developed countries might limit the adoption of these drugs in the market.


Request a Free sample to learn more about this report.


The number of people diagnosed with diabetes in the U.S. was higher than that of other developed countries, such as the U.K. (3.5 million) and Australia (1.3 million) in 2022.


U.S. Diabetes Drugs Market Segmentation Analysis


By Drug Class Analysis


Based on drug class, the market is segmented into insulin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and others.


The GLP-1 receptor agonists segment held a larger market share in 2022 owing to the increasing demand for and sales of these drugs among the population due to their extensive advantages over conventional insulins. These include improved blood sugar control and weight loss.



  • As per the Novo Nordisk A/S annual report published in 2022, the sales of Ozempic drugs generated USD 5,994.4 million in revenue in 2022, an increase of 70.2% from 2021 in the U.S.


By Diabetes Type Analysis


Based on diabetes type, the market is segmented into type 1 diabetes and type 2 diabetes.


The type 2 diabetes segment held a dominant share of the market. The segment’s higher share was attributed to an increase in the prevalence of type 2 diabetes among the adult and young population across the country compared to type 1 diabetes.



  • As per data published by the Centers for Disease Control and Prevention (CDC) in 2021, about 90-95% of the diabetic population in the U.S. suffered from type 2 diabetes.


By Route of Administration Analysis


On the basis of route of administration, the market is segmented into oral, subcutaneous, and intravenous.


The subcutaneous segment held a larger share of the U.S. market in 2022. This was due to increased administration of insulin through the subcutaneous route and a rise in self-administration of insulin among diabetic patients.



  • According to an article published by the NCBI in February 2023, subcutaneous is the most common route of insulin administration as it is easy to administer and requires minimal skills.


By Distribution Channel Analysis


On the basis of distribution channel, the market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies.


The retail pharmacies segment held a dominant share of the U.S. market in 2022. The segment’s dominance was attributed to the increased demand for diabetes drugs among the population due to high disease prevalence across the nation. Moreover, increasing the presence of these prescription drugs by launching them across retail stores and pharmacies will further propel the segment’s growth.



  • According to an article published by CNBC LLC., in August 2023, the demand for prescription diabetes drugs increased among retailers with pharmacy businesses, such as Walmart, Kroger, and Rite Aida, owing to high demand across the nation.

  • According to an article published by Walmart, Inc. in June 2021, the retail giant announced the launch of the NovoLog Insulin (analog insulin) through its private ReliOn brand in the U.S.


List of Key Companies in U.S. Diabetes Drugs Market


Novo Nordisk A/S Dominates the Market due to Extensive Diabetes Drugs Portfolio 


The U.S. market is highly concentrated due to the presence of major players, such as Novo Nordisk A/S, Sanofi, and Lilly. Novo Nordisk A/S is estimated to dominate the market during the forecast timeframe owing to its extensive diabetes drugs portfolio and increasing emphasis on the production and launch of advanced drugs in the U.S. market.



  • In January 2023, the U.S. FDA approved Novo Nordisk’s oral drug for diabetes, Rybelsus, as an initial treatment to lower blood sugar levels.


Other major players, such as Sanofi and Lilly held a significant U.S. diabetes drugs market share owing to their high focus on mergers and acquisitions of other industry players with significant diabetes drug portfolios in the country. Other significant players operating in this market are Novartis AG, Boehringer Ingelheim International GmbH, AstraZeneca, Merck & Co., Inc., and others.


An Infographic Representation of U.S. Diabetes Drugs Market

To get information on various segments, share your queries with us



LIST OF KEY COMPANIES PROFILED:



  • Novo Nordisk A/S (Denmark)

  • Sanofi (France)

  • Merck & Co., Inc. (U.S.)

  • Lilly (U.S.)

  • AstraZeneca (U.K.)

  • Takeda Pharmaceutical Company Limited (Japan)

  • Boehringer Ingelheim International GmbH (Germany)

  • Novartis AG (Switzerland)

  • Johnson & Johnson Services, Inc. (U.S.)

  • Bayer AG (Germany)


KEY INDUSTRY DEVELOPMENTS:



  • March 2023: Sanofi announced the acquisition of Provention Bio Inc., which will add TZIELD, the disease-modifying treatment used to delay Stage 3 type 1 diabetes (T1D), to Sanofi’s diabetes treatment portfolio.

  • January 2023: The U.S. Food and Drug Administration (FDA) approved bexagliflozin (Brenzavvy) by TheracosBio for treating patients with type 2 diabetes.

  • January 2020: The FDA approved Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended-release tablets) manufactured by Lilly to lower blood sugar in adults with type 2 diabetes.


REPORT COVERAGE


An Infographic Representation of U.S. Diabetes Drugs Market

To get information on various segments, share your queries with us



The report provides a detailed analysis of the market. It focuses on key aspects, such as an overview of the prevalence of diabetes in the U.S., drug class, product launches, key industry developments, such as mergers, partnerships, acquisitions, and the impact of COVID-19 on the market. Besides this, it also offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market in recent years.


To gain extensive insights into the market, Request for Customization


Report Scope & Segmentation



















































ATTRIBUTE



DETAILS



Study Period



2019-2030



Base Year



2022



Estimated Year



2023



Forecast Period



2023-2030



Historical Period



2019-2021



Unit



Value (USD Billion)



Growth Rate



CAGR of 7.6% from 2023 to 2030



 


 


 


 


 


 


 


 


 


Segmentation



By Drug Class



  • Insulin

  • DPP-4 Inhibitors

  • GLP-1 Receptor Agonists

  • SGLT2 Inhibitors

  • Others



By Diabetes Type



  • Type 1

  • Type 2



By Route of Administration



  • Oral

  • Subcutaneous

  • Intravenous



By Distribution Channel



  • Online pharmacies

  • Hospital Pharmacies

  • Retail Pharmacies






Frequently Asked Questions

Fortune Business Insights says that the U.S. market was worth USD 30.47 billion in 2022.

The market is expected to exhibit a CAGR of 7.6% during the forecast period of 2023-2030.

By drug class, the GLP-1 segment accounts for a considerable share of the market.

Novo Nordisk A/S, Sanofi, and Lilly are the top players in the market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts
Speak to an Expert
  • 2019-2030
  • 2022
  • 2019-2021
  • 80
Multi-report Purchase Plan
    A Customized Plan Will be Created Based on the number of reports you wish to purchase
Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X